

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<i>Centocor should not be reflected in the matrix of consultees. While Centocor holds the licence for golimumab, Schering-Plough will be the consultee for the technology appraisal.</i>	<i>Schering Plough</i>		<i>Noted</i>	<i>After consultation with both Centocor and Schering Plough, Schering Plough are to be named on the matrix as the manufacturer for this appraisal.</i>